BPMC(Delisted)
Blueprint Medicines·NASDAQ
--
--(--)
Blueprint Medicines (BPMC) Financial Statements
Blueprint Medicines (BPMC) Cash Flow Statement
During Q1 2024, Blueprint Medicines (BPMC) generated -101.51M in cash flow from operating activities, 77.13M from investing activities, and 66.96M from financing activities. Click to view the cash flow statement and track how funds are moving through the company.
Cash Flow
Q1,2014 | Q1,2015 | Q1,2016 | Q1,2017 | Q1,2018 | Q1,2019 | Q1,2020 | Q1,2021 | Q1,2022 | Q1,2023 | Q1,2024 | TTM |
|---|
Start Date | Jan 1, 2014 | Jan 1, 2015 | Jan 1, 2016 | Jan 1, 2017 | Jan 1, 2018 | Jan 1, 2019 | Jan 1, 2020 | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2024 | -- |
End Date | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Net Cash Flows from Operating Activities | -6.61M -- | 4.89M +173.98% | 30.75M +528.85% | -31.08M -201.07% | -49.56M -59.47% | -80.19M -61.79% | -109.33M -36.34% | -125.78M -15.05% | -132.73M -5.52% | -122.96M +7.36% | -101.51M +17.44% | -- -- |
Depreciation and Amortization | 134.00K -- | 209.00K +55.97% | 386.00K +84.69% | 398.00K +3.11% | 780.00K +95.98% | 1.18M +51.03% | 1.57M +33.36% | 1.61M +2.36% | 1.63M +1.24% | 1.30M -19.90% | -383.00K -129.37% | -- -- |
Change in Working Capital | 4.00K -- | 15.35M +383550.00% | 44.71M +191.35% | -5.84M -113.06% | 1.49M +125.44% | -2.77M -286.87% | -19.14M -589.69% | -57.52M -200.55% | -60.76M -5.63% | -23.86M +60.72% | -40.31M -68.93% | -- -- |
Net Cash Flows from Investing Activities | -94.00K -- | -1.28M -1267.02% | -70.36M -5375.88% | 35.79M +150.86% | -219.13M -712.31% | 89.31M +140.76% | 59.86M -32.98% | 132.20M +120.84% | -41.09M -131.08% | 172.79M +520.52% | 77.13M -55.36% | -- -- |
Purchase of PPE and Intangible Assets | 94.00K -- | 19.00K -79.79% | 1.26M +6542.11% | 210.00K -83.36% | 6.31M +2905.71% | 1.77M -71.96% | 1.52M -13.84% | 173.00K -88.66% | 1.15M +566.47% | 2.58M +124.11% | 1.10M -57.28% | -- -- |
Increase in Investments | -- -- | -- -- | 69.22M -- | 18.00M -73.99% | 338.82M +1782.00% | 112.92M -66.67% | 139.25M +23.32% | 83.08M -40.34% | 39.94M -51.93% | 132.88M +232.71% | 200.16M +50.64% | -- -- |
Net Cash Flows from Financing Activities | 24.99M -- | -547.00K -102.19% | -804.00K -46.98% | -420.00K +47.76% | 3.06M +829.05% | 2.01M -34.32% | 310.15M +15322.68% | 7.01M -97.74% | 1.26M -81.97% | -- -- | 66.96M -- | -- -- |
Change in Capital Stock | 24.99M -- | 19.00K -99.92% | 29.00K +52.63% | 902.00K +3010.34% | 3.64M +303.88% | 2.04M -44.03% | 310.15M +15110.89% | 7.01M -97.74% | 1.26M -81.97% | -- -- | 18.40M -- | -- -- |
Increase in Capital Stock | 24.99M -- | 19.00K -99.92% | 29.00K +52.63% | 902.00K +3010.34% | 3.64M +303.88% | 2.04M -44.03% | 310.15M +15110.89% | 7.01M -97.74% | 1.26M -81.97% | -- -- | 18.40M -- | -- -- |
Effect of Foreign Exchange Rate Changes | -- -- | -- -- | -- -- | -- -- | -- -- | -16.00K -- | 50.00K +412.50% | -97.00K -294.00% | -197.00K -103.09% | 197.00K +200.00% | -145.00K -173.60% | -- -- |
Net Increase in Cash and Cash Equivalents | 18.28M -- | 3.06M -83.27% | -40.42M -1421.71% | 4.29M +110.61% | -265.63M -6296.15% | 11.12M +104.19% | 260.73M +2244.50% | 13.33M -94.89% | -172.75M -1395.65% | 50.03M +128.96% | 42.44M -15.17% | -- -- |
Cash and Cash Equivalents at Beginning of Period | 1.99M -- | 47.24M +2277.45% | 162.71M +244.43% | 53.34M -67.22% | 405.07M +659.47% | 73.43M -81.87% | 119.60M +62.88% | 689.80M +476.74% | 215.12M -68.81% | 124.90M -41.94% | 81.52M -34.73% | -- -- |
Cash and Cash Equivalents at End of Period | 20.27M -- | 50.30M +148.15% | 122.29M +143.13% | 57.62M -52.88% | 139.44M +141.99% | 84.55M -39.37% | 380.34M +349.84% | 703.14M +84.87% | 42.37M -93.97% | 174.93M +312.87% | 123.96M -29.14% | -- -- |
You can ask Aime
No Data
